Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Nayak-Kapoor, Asha, Hao, Zhonglin, Sadek, Ramses, Dobbins, Robin, Marshall, Lisa, Vahanian, Nicholas N., Jay Ramsey, W., Kennedy, Eugene, Mautino, Mario R., Link, Charles J., Lin, Ray S., Royer-Joo, SVolume:
6
Language:
english
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1186/s40425-018-0351-9
Date:
December, 2018
File:
PDF, 1.11 MB
english, 2018